The Patent Finder

Perfuse Therapeutics, Inc.

6 patents currently held · Updated Nov 16, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Oct 2040
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Feb 28, 2027
    The maintenance fee for Treatment of Glaucoma Using Endothelin Receptor Antagonists (US 11,738,007) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
  • 1 fee due Apr 17, 2027
    The maintenance fee for Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases (US 11,786,510) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
  • 1 fee due Jul 16, 2027
    The maintenance fee for Compositions for Treatment of Ocular Diseases (US 11,873,279) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 6 of 6

PatentTitleStatus Expires Confidence
US 11,738,007Treatment of Glaucoma Using Endothelin Receptor Antagonists
In force
 · Medium confidence
In forceMedium confidence
US 12,778,933Treatment of Glaucoma Using Endothelin Receptor Antagonists
In force
 · Low confidence
In forceLow confidence
US 11,873,279Compositions for Treatment of Ocular Diseases
In force
 · Medium confidence
In forceMedium confidence
US 12,735,411Compositions for Treatment of Ocular Diseases
In force
 · Low confidence
In forceLow confidence
US 11,786,510Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,622,894Pharmaceutical Compositions and Intravitreal Drug Delivery Systems for the Treatment of Ocular Diseases
In force
 · Medium confidence
In forceMedium confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 pending · 1 abandoned

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited